Welcome to Advanced Search

Models

About 99 results
Literature

CRISPR/Cas9‑mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice

Model Organisms:Mouse Product & Service:F9 Research field:Hemophilia

Literature

Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

Model Organisms:小鼠 Product & Service:PRKAG2 H530R Research field:Heart

室性心律失常 AAV9 基因治疗

Literature

In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR–dCas9- activator...

Model Organisms:小鼠 Product & Service:- Research field:Gene regulation

Pages

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

CRISPR-Cas9 technology Broad Institute genetically modified mouse

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Pages

Customizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!

F0 homozygous mice gene knockout Crispr/Cas projects immediate phenotype analysis research efficiency cost optimization.

At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.

Pages

SMOC Launched U-HuDTMbase®, Inclusive Resource Library of Innovative Therapeutic Target-Humanized Mouse Models, to Accelerate Novel Drug Discovery

U-HuDTMbase® is composed of more than 600 therapeutic target-humanized mouse models, including multiple background strains, and has covered almost all commonly studied areas, such as oncology, metabolism, immunity, inflammation and more.

Email Back to top